Indivior PLC (OTCMKTS:INVVY – Get Free Report) shares fell 1.8% during mid-day trading on Friday. The company traded as low as $21.64 and last traded at $21.8455. 8,100 shares traded hands during trading, an increase of 112% from the average session volume of 3,825 shares. The stock had previously closed at $22.25.
Indivior Stock Performance
The firm’s 50 day simple moving average is $21.85 and its 200 day simple moving average is $21.85. The firm has a market capitalization of $3.01 billion, a price-to-earnings ratio of 20.81 and a beta of 0.35.
Indivior Company Profile
Indivior is a pharmaceutical company focused on treatments for substance use disorders, particularly opioid use disorder, as well as select mental health conditions. Its products include SUBLOCADE, an extended-release buprenorphine injection, and SUBOXONE, a buprenorphine and naloxone treatment for opioid use disorder. The company also markets PERSERIS, an extended-release risperidone injection for schizophrenia. Indivior was established as an independent company in 2014 through a demerger from Reckitt Benckiser.
Further Reading
- Five stocks we like better than Indivior
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.
